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We present here the case of a 33­month­old male patient with Wolf­Hirschhorn syndrome (WHS) and who underwent 
tympanoplasty and myringotomy. WHS is caused by a rare chromosomal abnormality, which is the deletion of 
the short arm of chromosome number 4. The typical craniofacial features of WHS patients such as micrognathia, 
microcephaly and the muscular weakness can make using neuromuscular blocking agents and performing 
intubation difficult. Moreover, there are a few previous case reports showing that malignant hyperthermia occurred 
during and after an operation in which the anesthesia was done with inhalation agents, so special anesthetic care is 
needed when operating on a WHS patient. By carefully intubating the patient and using total intravenous anesthesia, 
we performed successful anesthesia without any complications. We describe here the anesthetic management of a 
WHS patient and we review the relevant literature. (Korean J Anesthesiol 2011; 60: 119­123)
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    Wolf­Hirschhorn syndrome (WHS) is a very rare hereditary 
disease that shows a deletion of the distal short arm of 
chromosome 4 and particularly the 4p16.3 domain [1]. 
Patients with WHS are characterized by typical craniofacial 
features such as hypertelorism and a “Greek warrior helmet 
appearance” of the nose, microcephaly, a high forehead with 
prominent glabella, ocular hypertelorism, epicanthus, highly 
arched eyebrows, a short philtrum, a down­turned mouth, 
micrognathia and underdeveloped ears [1,2]. The prevalence 
of WHS has been reported to be approximately 1 : 50,000 and 
it shows a female predilection at a ratio of 2 : 1 [1]. All these 
patients have prenatal­onset growth deficiency, postnatal 
growth retardation and hypotonia with under­developed 
muscles [2]. These patients have characteristic musculo­skeletal 
anomalies, congenital heart defects, hearing loss, urinary tract 
malformations and structural brain abnormalities. Patients with 
WHS commonly have the concurrent presence of seizure, and 
the prognosis of these patients is very poor. Thirty­four percent 
of these patients die of cardiac failure or pneumonia at the age 
of < 2 years [1­3]. 120 www.ekja.org
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    A diagnosis of WHS is tentatively made based on the findings 
such as the gross facial appearance, developmental delay, 
psychomotor retardation and seizure, and it is established 
based on a loss of the Wolf­Hirschhorn critical region (WHCR) 
(chromosome 4p16). Using fluorescence in situ hybridization, a 
loss of the WHCR can be confirmed at a frequency of  > 95% [1,2].
    Patients with WHS are in need of corrective surgery due 
to the presence of various types of anomalies, and general 
anesthesia is performed in many cases. But due to the presence 
of various types of anomalies, managing the airway, regulating 
the muscle relaxation and controlling the vital signs during the 
surgery can be difficult. Moreover, there are also case studies 
that have reported the postoperative occurrence of malignant 
hyperthermia [4,5]. We performed total intravenous anesthesia 
(TIVA) in a patient who was diagnosed with WHS. We report 
here on our case along with a review of the relevant literature.
Case Report
    A 33­month­old male baby whose height and weight were 
88 cm and 11.35 kg, respectively, visited our hospital to 
undergo tympanoplasty and myringotomy for the bilateral 
ears under general anesthesia. The patient was born through 
a normal delivery and he had a weight of 2.67 kg at birth. 
From approximately one year old on, the patient presented 
several times with febrile seizure. At the time of admission, 
the patient had a height and a weight that were less than the 
third percentile. The patient’s motor ability was such that he 
could not stand alone without manual support. The patient 
also presented with such symptoms as motor and intellectual 
developmental delay and he had no responses to toys.
    The patient also had microcephaly and characteristic facial 
dysmorphism (Fig. 1). Both parents had no abnormal findings 
in their family medical histories. The patient had never 
experienced anesthesia. The parents had normal findings 
on genetic testing. But on gene analysis, the patient had 
46XY der(4)t(4;;)(p16;;) and this led to the diagnosis of WHS 
(Fig. 2). Due to continual rehabilitation, the patient could 
respond to calling his name. The patient also had an attention 
span of approximately 20 minutes in length and the verbal 
communication ability of approximately an 11 month old 
child. The patient frequently fell due to his unstable gait, but his 
developmental status was such that he could walk alone.
    On physical examination, the patient had no other findings 
other than what had been previously confirmed. There were 
no notable findings on the pre­operative work­up. There 
were no other prescribed drugs except phenobarbital for the 
management of seizure. The patient showed normal cardiac 
rhythm on echocardiography (EKG) and on auscultation, 
the patient showed normal cardiac sounds without a cardiac 
murmur. On the airway test, the patient had an inter­incisional 
distance of 3.1 cm for the maximal mouth opening and a 
thyromental distance of 4.3 cm, which extended from the 
thyroid notch to the chin. Based on these findings, the patient 
was grade II on the classification system of Mallampati. The 
neck movement showed flexion of  > 35 degrees and extension 
of  > 80 degrees. These results showed that there were no 
restrictions of neck movement. Additionally, to confirm the 
presence of any anomaly of the airway tract in the patient, 
anterior and posterior radiography was done together with 
Fig. 1. The patient has typical craniofacial features such as micro-
cephaly, a high forehead with prominent glabella, ocular hyper-
telorism, epicanthus, highly arched eyebrows, a short philtrum, a 
down-turned mouth and micrognathia.
Fig. 2. Chromosomal study: 46XY der(4)t(4;;)(p16;;). There is a 
deletion of genetic material near the end of the short (p16) arm of 
chromosome 4.121 www.ekja.org
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lateral radiography of the cervical spine, but there were no 
abnormal findings.
    The patient was given an intramuscular injection of atropine 
0.2 mg prior to anesthesia. The preoperative vital signs included 
a heart rate of 110 times/min, a blood pressure of 90/60 mmHg, 
a respiratory rate of 20 breaths/min and a body temperature of 
36.2
oC. For the intraoperative management, the end­tidal partial 
pressure of carbon dioxide, the body temperature via a nasal 
cavity and the oxygen saturation were measured, along with 
monitoring the EKG. Prior to the induction of anesthesia, due to 
the concern for the difficulty of endotracheal intubation, oxygen 
was provided to a sufficient extent for more than approximately 
three minutes. For the induction and maintenance of 
anesthesia, midazolam 0.1 mg/kg was intravenously injected 
once by using a remifentanil continuous infusion system 
(Orchestra
Ⓡ, Base Primea, Fresinius Vial, France), and this was 
set at a rate of 0.20-0.40 μg/kg/min. Following confirmation 
of easy ventilation, rocuronium 0.6 mg/kg was intravenously 
injected. Respiratory control was done using a mask. 
Endotracheal intubation was performed using a tube with an 
intratracheal lumen of 4.0 mm, which is a smaller size than is 
normally used for a patient of this age. For the laryngoscopic 
view, the patient was grade IIa on the modified Cormack and 
Lehane scoring system. Only part of patient’s glottis and vocal 
cords were visible, but endotracheal intubation was completed 
with no great difficulty. Oxygen and air were supplied at a rate 
of 2 L/min and 3 L/min, respectively. The intraoperative vital 
signs included a heart rate of 150-170 times/min and oxygen 
saturation of 97-100%. During anesthesia, the patient showed 
no specific abnormalities of the vital signs, and midazolam 0.1 
mg/kg was further administered during surgery to maintain the 
anesthesia. The surgical time was 25 minutes and the anesthetic 
time was 40 minutes. The body temperature was 37.4
oC and 
37.9
oC immediately after surgery was initiated and immediately 
before it was completed, respectively. The end­tidal partial 
pressure of carbon dioxide was maintained at 30-35 mmHg. 
The surgical procedure was completed with no great difficulty. 
After the patient made a recovery of spontaneous respiration to 
a sufficient extent, glycopyrrolate 0.1 mg and pyridostigmine 2.5 
mg were intravenously injected to reverse the muscle relaxation, 
and this was followed by extubation. The time from the end of 
surgery to extubation was about 10 minutes. A total of 25 ml of 
fluids, including 1 : 4 dextrose and sodium chloride solution, 
had been intraoperatively administered. The patient showed 
stable vital signs without notable complications in a recovery 
room. Due to the identification of a fever of 37.8
oC, the patient 
received continual measurement of the body temperature.
    The fever persisted following discharge from the recovery 
room. Seven hours following the discharge from a recovery 
room, the patient had a high fever of 39.0
oC and he had a seizure. 
The seizure was controlled by intravenous phenobarbital. 
But the high fever was persistently present even following the 
administration of antipyretics and antiepileptics. This led to the 
suspicion of delayed malignant hyperthermia. Yet the patient 
showed a congested and enlarged laryngopharynx following 
consultation with a pediatrician and an otolaryngologist. These 
findings were suggestive of an upper respiratory infection, so we 
administered antibiotics and additional antipyretics. The body 
temperature was normalized two days following the discharge 
from the recovery room. The patient was assumed to have had 
a fever due to upper respiratory infection rather than malignant 
hyperthermia. Thereafter, the patient recovered with no specific 
symptoms. The patient was discharged from the hospital on the 
sixth postoperative day.
Discussion
    According to Ginsburg and Purcell­Jones [5], malignant 
hyperthermia occurred in a 21­month­old female baby with 
WHS while anesthesia was being maintained with halothane 
for repairing a cleft palate. Those authors noted that good 
treatment outcomes were obtained using temperature­lowering 
therapy and dantrolene infusion. That study was the first 
reported case in which malignant hyperthermia occurred in 
a patient with WHS. According to Chen et al. [4], following the 
induction of anesthesia using halothane, succinylcholine and 
atracurium, malignant hyperthermia occurred two hours after 
a surgical procedure was initiated in a WHS patient. That was 
the first reported case in which the delayed type of malignant 
hyperthermia occurred in a WHS patient even following 
surgery. It has also been reported that the delayed type of 
malignant hyperthermia can occur even 11 hours after the 
completion of a surgical procedure [6].
    In our current study, a delayed type of malignant hyperthermia 
was suspected seven hours after the child was discharged from 
a recovery room due to the presence of a high fever of 39.0 
and this high was accompanied by seizure. The symptoms of 
the delayed type of malignant hyperthermia are tachypnea, 
tachycardia, hyperthermia and metabolic acidosis etc. [6]. But 
our patient showed all these symptoms of the delayed type 
of malignant hyperthermia except metabolic acidosis. So it 
was difficult to diagnose the disease. If such symptoms are 
developed, anesthesiologists must consider other possible 
diseases such as malignant hyperthermia, atelectasis, 
infections, overheating, a reaction to medications and so on [7]. 
But the patient in our case showed a congested and enlarged 
laryng  opharynx and these findings were suggestive of an upper 
respiratory infection. Further, the symptoms disappeared after 
administering antibiotics and additional antipyretics. So we 
think that the fever developed due to an upper respiratory 122 www.ekja.org
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infection rather than being due to the delayed type of malignant 
hyperthermia. 
    During induction and maintenance of anesthesia for a patient 
with WHS, anesthesiologist must not use any drugs and perform 
procedures that could trigger malignant hyperthermia [7]. The 
anesthetic drugs that trigger malignant hyperthermia include 
ether, halothane, enflurane, isoflurane, sevoflurane, and the only 
currently used depolarizing muscle relaxants (succinylcholine) 
[8]. The safe anesthetics consist of nitrous oxide, xenon, 
barbiturates, benzodiazepines, etomidate, propofol, narcotics, 
local anesthetics and nondepolarizing muscle relaxants 
[7,8]. Before using anesthetic machines for patients who are 
susceptible to malignant hyperthermia, the anesthetic machines 
need to be cleansed of potent volatile agents by removal or 
sealing of the vaporizers, changing the soda lime, perhaps 
replacing a fresh gas outlet hose, and using a disposable circuit 
with a flow of 10 L/min for 5 minutes [7,8]. 
    If fever develops in the patient with WHS during and 
after anesthesia, then anestheologists should consider the 
possibilities of malignant hyperthermia and other causes 
too. A variety of unusual conditions may resemble malignant 
hyperthermia during anesthesia. These include iatrogenic 
overheating, infection, transfusion reaction, central nervous 
system dysfunction, allergic reactions, pheochromocytoma, 
thyrotoxicosis, drug induced hyperthermia (i.e., tricyclic 
antidepressants, monoamine oxidase inhibitors, anticho­
linergics, amphetamines etc.), machine valve malfunction and 
rebreathing, as well as faulty equipment [7­9]. The presence of 
an elevated temperature in the immediate postoperative patient 
can be associated with conditions such as sepsis or a reaction 
to medication and this requires appropriate investigation 
[7]. The response to antipyretics as well the clinical setting is 
often helpful in differentiating this response from malignant 
hyperthermia.
    According to Ginsburg and Purcell­Jones [5], during the 
induction of 21­month­old female baby with WHS, tracheal 
intubation was difficult because of poor visualization of the 
glottis and intubation was eventually achieved with 3.5 mm 
endotracheal intubation tube, which is smaller than usual. 
Special attention should be paid to the airway management 
because patients with WHS have various craniofacial anomalies. 
Before the induction of anesthesia, the patient’s airway tract 
must be intensively examined and anestheologists should 
prepare for any possibility of difficult intubation [10].
    After a patient’s airway tract is thoroughly examined, 
induction of anesthesia in patients with craniofacial anomalies 
should be carefully done [10,11]. Maintaining spontaneous 
breathing and the face mask ventilability are very important. 
Premedication agents that do not suppress spontaneous 
ventilation or the airway reflexes should be used [11]. Either 
traditional preoxygenation (3 or more minutes of tidal volume 
ventilation) or fast­track preoxygenation (i.e., four maximal 
breaths in 30 s) is effective in delaying arterial desaturation 
during subsequent apnea [10]. If face mask ventilability is 
confirmed, then a deeper sedation level or general anesthesia 
may be performed so as to ease performing laryngoscopy or 
intubation. But if ventilation is difficult or impossible, then 
neuromuscular blocking agent should be avoided [11]. To 
confront a critical situation, it is considered mandatory that 
all the necessary instruments and devices should be easily 
and readily available [10,11]. We thought that endotracheal 
intubation could be difficult in our patient, so we carefully took 
the patient’s medical history, we examined the airway tract 
and the relevant tests were performed. There were no typical 
abnormalities observed. We conducted all the procedures with 
caution, so endotracheal intubation was done with no great 
difficulty and the induction of anesthesia could be safely done. 
    We report on our anesthetic experience with a WHS patient 
who had the typical craniofacial features, anomalies of multiple 
organs and developmental delay as a result of the deletion of 
p16.3 of chromosome 4. Difficult endotracheal intubation and 
the occurrence of malignant hyperthermia can be predicted 
when performing anesthesia for patients with WHS. With 
careful anesthetic managements, we were able to perform 
successful, safe anesthesia. However, it should be kept in mind 
that a high fever after anesthesia in WHS patient could develop 
due to not only malignant hyperthermia but also other causes 
such as infection, under­lying disease, iatrogenic causes, 
equipment problems and so on. 
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